Literature DB >> 20473757

Incidence of malignancy in Japanese patients with rheumatoid arthritis.

Toru Yamada1, Ayako Nakajima, Eisuke Inoue, Eiichi Tanaka, Atsuo Taniguchi, Shigeki Momohara, Hisashi Yamanaka.   

Abstract

To determine the incidence of malignancy and site-specific malignancies in Japanese patients with rheumatoid arthritis (RA). In a prospective large observational cohort study named IORRA, 7,566 patients with RA were enrolled from April 2001 to April 2005 and were followed up to October 2005. Occurrence of malignancy was originally collected by patient reports of IORRA survey biannually from April 2001 to October 2005, and was confirmed by medical records. Standardized incidence rate (SIR) of the observed-to-expected cancer incidence and 95% confidence intervals (95% CI) were then calculated. Factors obtained at first enrollment in IORRA were assessed for association with risk of malignancy using the Cox proportional hazards model. A total of 177 malignancies in 173 patients (58 in men, 115 in women) were identified during the observation period of 25,567 person-years. The age- and sex-standardized incidence rate of malignancy was 437.1 (men, 706.8; women, 366.1) per 100,000 person-years. The SIR of malignancy was slightly excess (SIR 1.18, [95% CI 1.02-1.37]) in all patients, but 1.29 (95% CI 0.99-1.67) in men, and 1.13 (95% CI 0.94-1.36) in women. A significant excess of lymphoma (SIR 6.07, [95% CI 3.71-9.37]) and lung cancer (SIR 2.29, [95% CI 1.57-3.21]), whereas decreased incidence of colorectal cancer (SIR 0.49, [95% CI 0.26-0.83]), were found. Male gender and older age were identified as risk factors for malignancy. A slight excess in the incidence of overall malignancy and highly excess of lymphoma in Japanese RA patients was demonstrated.

Entities:  

Mesh:

Year:  2010        PMID: 20473757     DOI: 10.1007/s00296-010-1524-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  36 in total

1.  Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA.

Authors:  A Nakajima; E Inoue; E Tanaka; G Singh; E Sato; D Hoshi; K Shidara; M Hara; S Momohara; A Taniguchi; N Kamatani; H Yamanaka
Journal:  Scand J Rheumatol       Date:  2010       Impact factor: 3.641

2.  Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis.

Authors:  Carl Turesson; W Michael O'Fallon; Cynthia S Crowson; Sherine E Gabriel; Eric L Matteson
Journal:  J Rheumatol       Date:  2002-01       Impact factor: 4.666

3.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

Review 4.  Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment.

Authors:  L Georgescu; G C Quinn; S Schwartzman; S A Paget
Journal:  Semin Arthritis Rheum       Date:  1997-06       Impact factor: 5.532

5.  Risk of malignancy among patients with rheumatic conditions.

Authors:  E Thomas; D H Brewster; R J Black; G J Macfarlane
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

6.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

7.  Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis.

Authors:  Takeshi Kuroda; Naohito Tanabe; Takashi Harada; Syuichi Murakami; Hisashi Hasegawa; Minoru Sakatsume; Masaaki Nakano; Fumitake Gejyo
Journal:  Clin Rheumatol       Date:  2005-11-03       Impact factor: 2.980

8.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-05

Review 9.  Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review.

Authors:  S F Kingsmore; B D Hall; N B Allen; J R Rice; D S Caldwell
Journal:  J Rheumatol       Date:  1992-09       Impact factor: 4.666

10.  Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan.

Authors:  Hisashi Yamanaka; Eisuke Inoue; Gurkirpal Singh; Eiichi Tanaka; Ayako Nakajima; Atsuo Taniguchi; Masako Hara; Taisuke Tomatsu; Naoyuki Kamatani
Journal:  Mod Rheumatol       Date:  2007-08-20       Impact factor: 3.023

View more
  21 in total

1.  Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study.

Authors:  Hai-Long Wang; Yong-Ming Zhou; Guang-Zhao Zhu; Zhu Yang; Bao-Jin Hua
Journal:  Clin Rheumatol       Date:  2017-05-16       Impact factor: 2.980

2.  No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan.

Authors:  Wen-Kuan Huang; Meng-Jiun Chiou; Chang-Fu Kuo; Yung-Chang Lin; Kuang-Hui Yu; Lai-Chu See
Journal:  Rheumatol Int       Date:  2014-03-27       Impact factor: 2.631

3.  Epstein-Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders.

Authors:  Kozue Ejima-Yamada; Yumi Oshiro; Seiichi Okamura; Tomoaki Fujisaki; Yasuhito Mihashi; Kazuo Tamura; Tomoko Fukushige; Masaru Kojima; Kazutoshi Shibuya; Morishige Takeshita
Journal:  Virchows Arch       Date:  2016-11-18       Impact factor: 4.064

Review 4.  RS3PE: Clinical and Research Development.

Authors:  Hongbin Li; Roy D Altman; Qingping Yao
Journal:  Curr Rheumatol Rep       Date:  2015-08       Impact factor: 4.592

Review 5.  Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.

Authors:  Alexis L Franks; Jill E Slansky
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

6.  Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort.

Authors:  Yoko Shimizu; Ayako Nakajima; Eisuke Inoue; Kumi Shidara; Naoki Sugimoto; Yohei Seto; Eiichi Tanaka; Shigeki Momohara; Atsuo Taniguchi; Hisashi Yamanaka
Journal:  Clin Rheumatol       Date:  2017-04-28       Impact factor: 2.980

7.  Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.

Authors:  Seiji Kondo; Kazuki Tanimoto; Kozue Yamada; Goichi Yoshimoto; Eiichi Suematsu; Tomoaki Fujisaki; Yumi Oshiro; Kazuo Tamura; Morishige Takeshita; Seiichi Okamura
Journal:  Virchows Arch       Date:  2013-03-14       Impact factor: 4.064

Review 8.  Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?

Authors:  George E Fragoulis; Katerina Chatzidionysiou
Journal:  Clin Rheumatol       Date:  2019-12-13       Impact factor: 2.980

9.  Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database.

Authors:  Yohei Seto; Eiichi Tanaka; Eisuke Inoue; Ayako Nakajima; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka
Journal:  Mod Rheumatol       Date:  2011-03-20       Impact factor: 3.023

10.  Lung cancer and interstitial lung diseases: a systematic review.

Authors:  Kostas Archontogeorgis; Paschalis Steiropoulos; Argyris Tzouvelekis; Evangelia Nena; Demosthenes Bouros
Journal:  Pulm Med       Date:  2012-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.